Literature DB >> 16677861

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein.

M A Stukova1, S Sereinig, N V Zabolotnyh, B Ferko, C Kittel, J Romanova, T I Vinogradova, H Katinger, O I Kiselev, A Egorov.   

Abstract

We generated several attenuated recombinant influenza A vectors expressing the Mycobacterium tuberculosis early secretory antigenic target (ESAT-6) protein. The ESAT-6 protein was recently identified as one of the most promising protective antigens for cell-mediated immunity. The obtained vectors appeared to be capable of inducing ESAT-6 specific Th1 immune response in mice after intranasal immunization. We found that double immunization with two influenza vectors of different subtypes provided a significant level of protection in mice, when applied as prophylactic vaccine, as well as substantial therapeutic effect in mice with pre-established tuberculosis infection. Moreover, we found a strong synergistic effect when vaccination with Flu/ESAT-6 vectors was combined with isoniazid treatment, resulting in a dramatic reduction of bacterial load in the lungs of infected mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677861     DOI: 10.1016/j.tube.2006.01.010

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  12 in total

Review 1.  Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.

Authors:  Zhidong Hu; Shui-Hua Lu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

2.  Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Authors:  Katherine Kedzierska; Joan M Curtis; Sophie A Valkenburg; Lauren A Hatton; Hiu Kiu; Peter C Doherty; Lukasz Kedzierski
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

3.  Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.

Authors:  Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Mingtao Zeng
Journal:  Front Immunol       Date:  2015-04-21       Impact factor: 7.561

4.  Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles.

Authors:  Dhananjayan Dhanasooraj; R Ajay Kumar; Sathish Mundayoor
Journal:  Int J Nanomedicine       Date:  2013-02-25

Review 5.  Engineering influenza viral vectors.

Authors:  Junwei Li; Maria T Arévalo; Mingtao Zeng
Journal:  Bioengineered       Date:  2012-08-24       Impact factor: 3.269

6.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

7.  Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Authors:  Christoph Jindra; Bettina Huber; Saeed Shafti-Keramat; Markus Wolschek; Boris Ferko; Thomas Muster; Sabine Brandt; Reinhard Kirnbauer
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

Review 8.  Recombinant vectors as influenza vaccines.

Authors:  Sarah A Kopecky-Bromberg; Peter Palese
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

9.  Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine.

Authors:  Elizabeth K Roediger; Kapilan Kugathasan; XiZhong Zhang; Brian D Lichty; Zhou Xing
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

10.  Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb Infection.

Authors:  Helena Strand Clemmensen; Niels Peter Hell Knudsen; Rolf Billeskov; Ida Rosenkrands; Gregers Jungersen; Claus Aagaard; Peter Andersen; Rasmus Mortensen
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.